MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
| Autor: | Markus Schaich, Thomas Illmer, Christian Thiede, Silke Soucek, Gerhard Ehninger |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Adolescent Gene Expression Context (language use) Drug resistance Biology Disease-Free Survival Internal medicine Antineoplastic Combined Chemotherapy Protocols Gene expression Biomarkers Tumor medicine Humans Gene Survival analysis Aged Hematology Reverse Transcriptase Polymerase Chain Reaction Cytogenetics Middle Aged Prognosis Survival Analysis Neoplasm Proteins Treatment Outcome Leukemia Myeloid Acute Disease Immunology Tandem exon duplication Genes MDR Multidrug Resistance-Associated Proteins |
| Zdroj: | British Journal of Haematology. 128:324-332 |
| ISSN: | 1365-2141 0007-1048 |
| Popis: | Multi drug resistance (MDR) is a major obstacle for cancer therapy. The three major candidates accounting for the development of MDR in acute myeloid leukaemia (AML) are multi drug resistance gene (MDR1), multi drug resistance-related protein gene (MRP1) and lung resistance protein gene (LRP). So far, the differential impact of resistance gene expression on treatment outcome in AML is not clear. Therefore, we examined MDR1, MRP1 and LRP gene expression at diagnosis in 331 adult AML patients in the context of other known prognostic factors, such as age, disease status, cytogenetics and FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication mutational status. Median observation time was longer than 5 years [64.1 months (40.0-87.6)]. MDR1 expression proved to be an independent prognostic factor for outcome of induction therapy (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text